Prakt. lékáren. 2012; 8(1): 25-27

New medicinal substances in extemporaneous prescription, part 12 - propranolol hydrochloride

Zbyněk Sklenář1,2, Kateřina Horáčková2
1 Farmakologický ústav, 1. LF UK, Praha
2 Lékárna Na Rohožníku, Praha

Propranolol hydrochloride, sympatholytic non-selective beta blocker, is a terapeutic agent for the succesful treatment of infantile

hemangiomas. There is no commercially available any registered drug which contains propranolol-hydrochloride in Czech Republic.

Abroad there are a registered medicinal products intended only for adult patients with the fixed dose. Since June 2011 propranolol

hydrochloride has been available as a pharmaceutical substance for the extemporaneous preparation in pharmacies, thus simply preparation

of pediatric dosage form is possible.

Keywords: propranolol hydrochloride, antiarrhythmic agent, infantile hemangiomas, magistral preparation, pediatric dosage forms

Published: March 1, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Sklenář Z, Horáčková K. New medicinal substances in extemporaneous prescription, part 12 - propranolol hydrochloride. Praktické lékárenství. 2012;8(1):25-27.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Wynn RL, Meiller TF, Crossley HL. Drug information handbook for dentistry. 15th ed. Ohio: Lexi-Comp 2009: 1459-1462.
    2. Lüllmann H, Mohr K, Wehling M. Farmakologie a toxikologie. 1. české vyd. Praha: Grada Publishing s.r.o. 2002: 115.
    3. Gupta VD, Stewart KR. Stability of propranolol hydrochloride suspension and solution compounded from injection or tablets. Am J Hosp Pharm 1987; 44: 360-362. Go to original source...
    4. Státní ústav pro kontrolu léčiv, databáze léků. Dostupné z: http://www.sukl.cz/modules/medication/search.php [cit. 2011-11-15].
    5. Garin EH, Araya CE. Treatment of systemic hypertension in children and adolescents. Curr Opin Pediatr 2009; 21: 600-604. Go to original source... Go to PubMed...
    6. Truong MT, Perkins JA, Messner AH, Chang KW. Propranolol for the treatment of airway hemangiomas: A case series and treatment algorithm. Int J Pediatr Otorhinolaryngol 2010; 74(9): 1043-1048. Go to original source... Go to PubMed...
    7. Hermans DJ, van Beynum IM, Schultze Kool LJ, et al. Propranolol, a very promising treatment for ulceration in infantile hemangiomas: a study of 20 cases with matched historical controls. J Am Acad Dermatol 2011; 64(5): 833-838. Go to original source... Go to PubMed...
    8. Kim LH, Hogeling M, Wargon O, et al. Propranolol: useful therapeutic agent for the treatment of ulcerated infantile hemangiomas. J Pediatr Surg 2011; 46(4): 759-763. Go to original source... Go to PubMed...
    9. Leaute-Labreze C, Dumas DE, la Roque E, Hubice T, et al. Propranolol for severe hemangiomas of infanty. N Engl J Med 2008; 358(24): 2649-2651. Go to original source... Go to PubMed...
    10. Cheng JF, Gole GA, Sullivan TJ. Propranolol in the management of periorbital infantile haemangioma. Clin Experiment Ophthalmol 2010; 38(6): 547-553. Go to original source... Go to PubMed...
    11. Maguiness SM, Frieden IJ. Current management of infantile hemangiomas. Semin Cutan Med Surg 2010; 29(2): 106-114. Go to original source... Go to PubMed...
    12. Schiestl C, Neuhaus K, Zoller S, et al. Efficacy and safety of propranolol as first-line treatment for infantile hemangiomas. Eur J Pediatr 2011; 170(4): 493-501. Go to original source... Go to PubMed...
    13. Mihál V, Novák Z, Hůlková E, Michálková K. Kdy je indikována léčba infantilních hemangiomů propranololem? Pediatr praxi 2011; 12(2): 108-110.
    14. https://online.epocrates.com/noFrame/showPage.do?method=drugs&MonographId=115&ActiveSectionId=2 [cit. 2011-08-18].
    15. Pavlakovic H, Kietz S, Lauerer P, et al. Hyperkalemia complicating propranolol treatment of an infantile hemangioma. Pediatrics 2010; 126(6): 1589-1593. Go to original source... Go to PubMed...
    16. de Graaf M, Breur JM, Raphaël MF, et al. Adverse effects of propranolol when used in the treatment of hemangiomas: A case series of 28 infants. J Am Acad Dermatol 2011; 65(2): 320-327. Go to original source... Go to PubMed...
    17. Ahmed GH, Stewart PJ, Tucker IG. The stability of extemporaneous paediatric formulations of propranolol hydrochloride. Aust J Hosp Pharm 1988; 18(5): 312-318.
    18. Henry DW, Repta AJ, Smith FM, White SJ. Stability of propranolol hydrochoride suspension compounded from tablets. Am J Hosp Pharm 1986; 43(6): 1492-1495. Go to original source...
    19. Rowe RC, Sheskey PJ, Owen SC. Pharmaceutical excipients 2004 (Singleuser version). [CD-ROM]. Washington, DC: Pharmaceutical Press and American Pharmacists Association, 2004.

    Return to the content


    Pharmacy for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.